Edwards Lifesciences enters amended five-year credit agreement on Nov. 19, 2026
EW•Edwards Lifesciences entered an amended and restated five-year credit agreement on Nov. 19, 2026, providing a $750 million multi-currency unsecured revolving credit facility. The company may increase the facility by up to $375 million in aggregate.
1. Credit facility details
The agreement provides Edwards Lifesciences with a $750 million multi-currency unsecured revolving credit facility. The company may increase the agreement by up to $375 million in aggregate.




